Scientists at Verve Therapeutics in Boston conducted the inaugural human trial of base editing, using the treatment VERVE-101 to deactivate the PCSK9 gene in the liver. The gene regulates ‘bad’ cholesterol, and the one-time injection resulted in a significant LDL reduction of up to 55%. This milestone suggests a potential transformative approach to treat coronary artery disease. However, safety concerns emerged, with two serious adverse events, including a death. The findings, presented at the American Heart Association meeting, indicate both promise and challenges for this ground-breaking gene-editing technique.
Related Posts
Reverberations from Earthquakes Reveal New Details about Earth’s Inner Core
A new study published in Nature Communications has used the reverberations from earthquakes to reveal new details about the structure of the Earth’s inner core. For decades, there has been evidence to suggest that the inner core is made up of distinct layers, but their properties have remained mysterious. To better understand the inner core’s […]
Mediterranean diet improves semen quality
The Mediterranean diet, renowned for its health benefits, has recently garnered attention for its potential positive impact on male reproductive health. Amidst rising concerns over male infertility, characterized by issues such as impaired spermatogenesis, researchers are exploring lifestyle interventions to address this challenge. Studies have revealed a promising link between the Mediterranean diet and […]
High Blood Pressure in 30s Linked to Worse Brain Health in Later Life
A new study by UC Davis shows that having high blood pressure in your 30s is linked to worse brain health around age 75, particularly for men. The research found that people with high blood pressure between ages 30 to 40 had significantly lower regional brain volumes and worse white matter integrity, both of which […]